Tectonic Therapeutic (TECX) EBITDA (2017 - 2026)
Tectonic Therapeutic (TECX) posted quarterly EBITDA of -$27.3 million for Q1 2026, down 49.2% year-over-year from -$53.7 million in Q1 2025, and down 26.89% quarter-over-quarter from -$21.5 million in Q4 2025.
Tectonic Therapeutic (TECX) EBITDA (2017 - 2026) Analysis & Trends
Tectonic Therapeutic (TECX) has reported EBITDA for 10 consecutive years, with -$27.3 million the latest figure, recorded in Q1 2026.
- In Q1 2026, EBITDA fell 49.2% year-over-year to -$27.3 million; the TTM figure through Mar 2026 stood at -$93.0 million (down 46.87% YoY), while the FY2025 annual figure was -$84.0 million, down 44.85% from the prior year.
- EBITDA eased to -$27.3 million in Q1 2026 per TECX's latest filing, from -$21.5 million in the prior quarter.
- Across five years, EBITDA topped out at -$9.4 million in Q4 2023 and bottomed at -$29.4 million in Q1 2022.
- Historically, EBITDA has averaged -$19.4 million across 5 years, with a median of -$21.5 million in 2025.
- Annual changes were most pronounced in 2023 — EBITDA soared 62.89% — and 2025, when it plunged 95.53%.
- Tectonic Therapeutic's EBITDA stood at -$25.3 million in 2022, then jumped by 62.89% to -$9.4 million in 2023, then plunged by 49.25% to -$14.0 million in 2024, then tumbled by 53.78% to -$21.5 million in 2025, then decreased by 26.89% to -$27.3 million in 2026.
- Business Quant data shows TECX's EBITDA at -$27.3 million in Q1 2026, -$21.5 million in Q4 2025, and -$21.9 million in Q3 2025.
Powered by 
Peer Comparison
| # | Company | Market Cap | Enterprise Value | Gross Profit (Qtr) | EBITDA (Qtr) |
|---|---|---|---|---|---|
| 1 | Vertex Pharmaceuticals | 128.13 Bn | 120.28 Bn | 2.84 Bn | 1.25 Bn |
| 2 | Regeneron Pharmaceuticals | 112.33 Bn | 104.33 Bn | 3.93 Bn | 1.29 Bn |
| 3 | Argenx Se | 53.24 Bn | 48.05 Bn | 1.41 Bn | 493.00 Mn |
| 4 | Revolution Medicines | 43.64 Bn | 43.64 Bn | - | -505.13 Mn |
| 5 | BeOne Medicines | 39.27 Bn | 34.17 Bn | 1.53 Bn | 325.05 Mn |
| 6 | MindWalk Holdings | 35.32 Bn | 35.31 Bn | 1.82 Bn | -2.33 Bn |
| 7 | Royalty Pharma | 33.72 Bn | 35.84 Bn | - | 133.12 Mn |
| 8 | Alnylam Pharmaceuticals | 30.58 Bn | 27.27 Bn | 992.69 Mn | 231.44 Mn |
| 9 | Insmed | 27.01 Bn | 25.85 Bn | 358.27 Mn | -1.55 Mn |
| 10 | Tectonic Therapeutic | 671.50 Mn | 671.50 Mn | - | -24.22 Mn |
Historic Data
Download Data| Date | Value |
|---|---|
| Jun 30, 2026 | -24.22 Mn |
| Mar 31, 2026 | -27.30 Mn |
| Dec 31, 2025 | -21.52 Mn |
| Sep 30, 2025 | -21.89 Mn |
| Jun 30, 2025 | -22.33 Mn |
| Mar 31, 2025 | -18.30 Mn |
| Dec 31, 2024 | -13.99 Mn |
| Sep 30, 2024 | -19.64 Mn |
| Jun 30, 2024 | -11.42 Mn |
| Mar 31, 2024 | -12.97 Mn |
| Dec 31, 2023 | -9.37 Mn |
| Sep 30, 2023 | -10.11 Mn |
| Jun 30, 2023 | -10.63 Mn |
| Mar 31, 2023 | -25.22 Mn |
| Dec 31, 2022 | -25.26 Mn |
| Sep 30, 2022 | -22.99 Mn |
| Jun 30, 2022 | -27.77 Mn |
| Mar 31, 2022 | -29.42 Mn |
| Dec 31, 2021 | -27.96 Mn |
| Sep 30, 2021 | -32.62 Mn |